Table 3. The imaging features of different histopathological entities.
|
IMT |
PPB |
Adenocarcinoma |
Hemangioma |
Pneumocytoma |
MCT |
LELC |
Total |
|
|
N of cases |
10 (41.6%) |
6 (25%) |
2 (8.3%) |
2 (8.3%) |
2 (8.3%) |
1 (4.2%) |
1 (4.2%) |
24 |
|
Age (y) (median, 25p – 75p) |
8.5 (6 – 12) |
3 (2 – 4) |
9, 15* |
5 mo, 9 mo* |
13, 15* |
11 mo* |
16 |
7.5 (2 – 12) |
|
L:R |
4:6 |
3:3 |
0:2 |
1:1 |
1:1 |
0:1 |
0:1 |
9:15 |
|
Peripheral location |
8 (80%) |
6 (100%) |
0 |
2 (100%) |
1 (50%) |
1 (100%) |
0 |
18 (75%) |
|
Greatest axial diameter (cm) (Median, 25p – 75p) |
7.9 (5.5 – 10) |
7.75 (6.8 – 9.2) |
4, 4.4a |
4, 8.2a |
2.3, 2.4a |
15 |
2.8 |
7.25 (4.25 – 9.6) |
|
Calcification |
8 (80%) |
1 (16.7%) |
0 |
0 |
0 |
1 (100%) |
0 |
10 (41.6%) |
|
Atelectasis |
6 (60%) |
6 (100%) |
1 (50%) |
1 (50%) |
0 |
1 |
0 |
15 (62.5%) |
|
Heterogeneous enhancement |
5 (62.5%)b |
5 (100%)b |
1 (50%) |
0b |
0b |
NE |
NA |
11 (57.9%) |
|
Lobulated margin |
6 (60%) |
4 (66.6%) |
2 (100%) |
2 (100%) |
1 (50%) |
0 |
0 |
15 (62.5%) |
|
Pleural effusion |
7 (70%) |
3 (50%) |
0 |
0 |
0 |
1 (100%) |
0 |
11 (45.8%) |
|
Lymphadenopathy |
4 (40%) |
0 |
1 (50%) |
0 |
0 |
0 |
1 (100%) |
6 (25%) |
|
Local invasion |
7 (70%) |
2 (33.3%) |
1 (50%) |
0 |
0 |
0 |
0 |
10 (41.6%) |
|
Metastasis |
0 |
0 |
1 (50%) |
0 |
0 |
0 |
1 (100%) |
1 (4.2%) |
Numbers in brackets are column percentages. *Patients’ ages are given separately. aTumor sizes are given separately. bTwo patients with IMT and one with PPB did not undergo preoperative CT or MRI with intravenous contrast. Homogeneous contrast enhancement was observed in two patients with hemangioma and one patient with pneumocytoma. IMT, inflammatory myofibroblastic tumor; PPB, pleuropulmonary blastoma; CT, computed tomography; MRI, magnetic resonance imaging; MCT, mature cystic teratoma; LELC, lymphoepithelioma-like carcinoma; NE, no enhancement; NA, not available; mo, months; L:R: left lung:right lung.